ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.768,96
0,33%
S&P 500
5.312,24
0,17%
Dow Jones
39.822,19
-0,45%
Euro vs US Dollar
1,08633
-0,10%
Bitcoin
69.388,49
4,70%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. AN2 Therapeutics Inc (ANTX)

  7. AN2 Therapeutics Inc (ANTX) News

ANTX

AN2 Therapeutics (ANTX)

AN2 Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ANTX
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202422h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
14/05/202422h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
14/05/202422h01Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANTXAN2 Therapeutics Inc
14/05/202422h01Business WireAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
28/03/202421h10Business WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
13/02/202423h11Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANTXAN2 Therapeutics Inc
12/02/202413h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
12/02/202412h45Business WireAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
30/01/202422h10Business WireAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
19/01/202400h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
17/01/202423h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
12/01/202423h08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
12/01/202401h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
05/01/202400h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
05/01/202400h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
02/01/202422h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
02/01/202422h36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
17/11/202300h57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322h05Business WireAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
06/11/202313h00Business WireAN2 Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ANTXAN2 Therapeutics Inc
18/10/202313h00Business WireAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
11/10/202306h01Business WireAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023NASDAQ:ANTXAN2 Therapeutics Inc
04/10/202301h21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
02/10/202322h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
29/09/202323h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
29/09/202322h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
26/09/202313h00Business WireAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaNASDAQ:ANTXAN2 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ANTX

Kürzlich von Ihnen besucht

AMEX
HHK
NASDAQ
ACTKX
Amundi Climate Transitio...
NASDAQ
EUCRW
Eucrates Biomedical Acqu...
COIN
EVYBTC
EveryCoin
KOSPI
510015
Daishin Wheat Futures Et...
LSE
QJ43
Morg.st.b.v 25
TSXV
AMR
AM Resources
LSE
76QP
Municplty 39
USOTC
MVMDF
Mountain Valley MD (QB)
ASX
PLL
Piedmont Lithium
NASDAQ
AAYXFXX
Barclays Bank Plc Point ...
BOV
MATD3R
Hospital Mater Dei S.A ON
BIT
UB5FW0
Unicredit Bank
NASDAQ
PLCC
Paulson Capital (Delaware) Corp.
NYSE
DHM.L
NYSE
BQ
Boqii
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten